BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-five research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $87.22.
A number of research analysts recently commented on BMRN shares. Stifel Nicolaus decreased their price target on BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Tuesday, November 3rd. HC Wainwright reaffirmed a “neutral” rating and issued a $60.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday, November 3rd. Morgan Stanley cut their price objective on shares of BioMarin Pharmaceutical from $119.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, November 13th. BMO Capital Markets reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Finally, Canaccord Genuity Group raised their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a report on Monday, August 10th.
Check Out Our Latest Research Report on BMRN
BioMarin Pharmaceutical Price Performance
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.28. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a positive return on equity of 5.58% and a negative net margin of 0.52%. The company’s revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.12 EPS. As a group, research analysts expect that BioMarin Pharmaceutical will post 2.20 EPS for the current fiscal year.
Insider Buying and Selling at BioMarin Pharmaceutical
In related news, EVP Gregory Friberg sold 5,147 shares of the stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $58.81, for a total transaction of $302,695.07. Following the sale, the executive vice president owned 42,585 shares in the company, valued at approximately $2,504,423.85. This trade represents a 10.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.68% of the company’s stock.
Institutional Investors Weigh In On BioMarin Pharmaceutical
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA bought a new position in BioMarin Pharmaceutical in the second quarter valued at about $811,962,000. Caisse de depot et placement du Quebec acquired a new position in BioMarin Pharmaceutical during the second quarter worth about $70,749,000. Bank of New York Mellon Corp acquired a new position in BioMarin Pharmaceutical during the second quarter worth about $66,107,000. Edmond DE Rothschild Holding S.A. bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth about $39,312,000. Finally, Palo Alto Investors LP bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth about $39,068,500. 98.71% of the stock is currently owned by institutional investors.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
See Also
- Five stocks we like better than BioMarin Pharmaceutical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
